Climb Bio, Inc.
PublicClimb Bio, Inc. is now publicly traded
The data on this page reflects Climb Bio, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
May 4, 2026
Total Funding Raised
$110.08M
Company Overview
Eliem Therapeutics (NAS: CLYM) is a biotechnology company focused on developing therapeutics for immune-mediated diseases, with its lead product candidate, budoprutug, being an anti-CD19 monoclonal antibody that shows promise in treating various B-cell-mediated conditions through B-cell depletion.
Sector
Biotech
AI Layer
Non-AI
Keywords
Climb Bio, Inc. Comparables
Compare Climb Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biogen | 75% | |
| Cerium Pharmaceuticals, Inc. | 54% | |
Climb Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | May 4, 2026 |
Key People
Founding team and executive leadership
Climb Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Private Placement |
| ADAR1 Capital Management | Private Placement |
| RA Capital Management | Private Placement |
| Ally Bridge Group | Private Placement |
| Adage Capital Partners, L.P. | Private Placement |
| Driehaus Capital Management | Private Placement |
| Cormorant Asset Management | Private Placement |
Climb Bio, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
